Trailing Twelve Months Revenue Growth: novavax.com (NVAX)

Public company logo of Novavax Pharma (NVAX)

Novavax, Inc. (NVAX) reduces capital expenditures by utilizing external partners for vaccine development and production, with the metric currently standing at -61.00. The current 12-month year-over-year sales trend illustrates revenue dynamics. Diversification of logistics routes ensures supply stability, while patent protection and strict facility certification create barriers to entry for new players.

NVAX (Novavax) Sales Growth YoY (TTM) history from 02/11/2024 to 11/18/2026

novavax.com (NVAX) - metric breakdowns and financial figures

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Fundamental company valuation:Novavax, Inc. - NVAX
Manufactured products of Novavax, Inc.

The investment attractiveness of Novavax, Inc. (NVAX) depends on the ability of the remaining core research team to monetize the current product pipeline. This indicator calculates the daily rolling revenue growth over the last twelve months, which allows this chart of LTM sales volume changes compared to the previous year to identify cooling demand and assess the real efficiency of business management following staff optimization.